Merck Gains Early-Stage Protease Inhibitor For HIV/AIDS Through Ambrilia Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing agreement includes rights to Ambrilia's lead compound PPL-100 in Phase I development as a once-daily, first-line oral therapy for HIV.